Shelley E. Crary

High Impact

Professor, Pediatric Hematology-Oncology

UAMS primary UA Little Rock

Also affiliated: University of North Carolina at Chapel Hill (2023); Children's Medical Center (2007–2013); Arkansas Children's Hospital (2013–2026); University Medical Center Groningen (2023); Duke University (2011); Utrecht University (2023); University of Michigan (2023); University of Arkansas Medical Center (2018–2026); Erasmus MC (2023); University Medical Center Utrecht (2023); Cook Children's Medical Center (2008); Center for Cancer and Blood Disorders (2010–2011); Duke Medical Center (2011); American Society of Pediatric Hemotology Oncology (2019); Amsterdam University Medical Centers (2023); The University of Texas Southwestern Medical Center (2005–2013); University of Amsterdam (2023); Erasmus University Rotterdam (2023); University of California, Berkeley (2019)

20 h-index 103 pubs 2,103 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Dr. Shelley E. Crary is a Professor of Pediatrics in the Division of Pediatric Hematology-Oncology at the University of Arkansas for Medical Sciences (UAMS) and Arkansas Children’s Hospital (ACH). She holds leadership positions as the Medical Director of the Arkansas Center for Bleeding Disorders and Director of Hematology at ACH. Dr. Crary also serves as Co-Director of the UAMS Clinical and Translational Science Pilot Program, focusing on advancing translational research and supporting career development for junior faculty and fellows.

Her research interests include the treatment of hematologic conditions in children, with recent publications addressing gene therapy for Hemophilia B, anticoagulant therapy for venous thromboembolism, and treatment practices for kaposiform hemangioendothelioma and vascular malformations. Dr. Crary also investigates pharmacokinetic properties of sclerotherapy agents and approaches to coagulopathy in patients with vascular anomalies. Her work has contributed to understanding long-term biological effects in sickle cell disease and defining pediatric refractory immune thrombocytopenia (ITP).

Dr. Crary is actively involved in medical education and mentorship, co-directing the UAMS Master’s in Clinical and Translational Sciences Scholarship Program and participating in the American Society of Hematology (ASH) Classical Hematology Mentorship Program. She earned her undergraduate degree from Washington University in St. Louis and her medical degree from Tulane University School of Medicine, followed by residency at Vanderbilt University and a fellowship at UT Southwestern Medical Center, where she also obtained a Master of Science in Clinical Science.

Metrics

h-index: 20
Publications: 103
Citations: 2,103

Positions

Professor, Pediatric Hematology-Oncology 2011–present

University of Arkansas for Medical Sciences Pediatrics Institutional directory

Selected Publications

Mental Health Evaluation in Patients with Vascular Malformations (2026)

Journal of Vascular Anomalies DOI OpenAlex
Bone mineral density, bone remodeling biomarkers, and hemostatic correlates in hemophilia and von Willebrand disease (2026)

Blood Advances 1 citation DOI OpenAlex
ReInspire: A Phase 2 Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA-Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (2026)

Journal of Investigative Dermatology DOI OpenAlex
HTRS2025.P1.27 Prevalence Vitamin D deficiency and risk factors for poor bone health in persons with Hemophilia A and B in Arkansas – A retrospective single institution study (2025)

Research and Practice in Thrombosis and Haemostasis DOI OpenAlex
Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study (2025)

Blood DOI OpenAlex
Multimodal neuroimaging and neurocognitive assessment in adolescents with and without sickle cell disease (2025)

Blood DOI OpenAlex
End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children (2025)

Blood DOI OpenAlex
Knowledge, interest, and willingness of hematologists and oncologists to care for adults with vascular anomalies (2025)

Journal of Thrombosis and Haemostasis 3 citations DOI OpenAlex
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment (2025)

JAMA 5 citations DOI OpenAlex
Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease (2025)

JAMA Network Open 1 citation DOI OpenAlex
Pediatric hematology: selected topics (2025)

DOI OpenAlex
The Functional Characterization of Venous Thromboembolic Disease (FUVID) study: rationale, design, and methods of a prospective, observational, multicenter study to evaluate mechanisms of exercise intolerance and dyspnea following pediatric pulmonary embolism (2024)

Research and Practice in Thrombosis and Haemostasis 4 citations DOI OpenAlex
Hemostasis and thrombosis risks and management in vascular anomalies (2024)

Hematology 2 citations DOI OpenAlex
Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children (2024)

Blood 1 citation DOI OpenAlex
Hypercoagulability Evaluation in Pediatric Kidney Transplant Recipients to Optimize Outcomes (2024)

Blood 1 citation DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

CUMG UAMS College of Medicine
GR034186-Crary-HRSA Great Plains Regional Hemophilia Network-UT University of Texas via UAMS ACHRI Flow Through
Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting UAMS ACHRI Flow Through